Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Gain on sale of PREBOOST® business

Impairment of intangible assets

Provision for (recovery of) credit losses

Gain on sale of ENTADFI® assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veru

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veru reports positive Phase III results for sabizabulin in COVID-19

Veru's positive Phase III trial results for sabizabulin in COVID-19 highlight its potential in reducing mortality.
Financially, challenges persist with decreased revenues and increased expenses, but the company is focused on growth strategies.
The company's strengths lie in sabizabulin's unique mechanism, clinical trial prioritization, and revenue generation plans.
Opportunities for Veru include commercializing sabizabulin, driving revenue growth, and advancing oncology trials.

Veru reports Q2 financial challenges but shows promise in clinical developments

Veru Inc. faced financial challenges in Q2 2023 with decreased net revenues and significant operating losses, prompting efforts to manage costs and explore strategic options.
Despite the financial hurdles, the company demonstrated strengths in clinical developments, securing additional funding, and pursuing growth opportunities in breast cancer and viral ARDS treatments.
Veru's focus on increasing revenues through marketing efforts, expanding distribution channels, and seeking strategic partnerships positions the company for future growth and success in the pharmaceutical industry.

Veru reports mixed Q3 results, eyes partnerships and market expansion

Veru Inc. faced challenges with a decrease in net revenues but achieved a net income for Q3 2023.
Strengths lie in promising results of enobosarm and sabizabulin studies, FDA clarity, and improved cash position.
Opportunities include expanding evaluation of sabizabulin, seeking partnerships, and market expansion through tenders.
The company needs to address challenges of net losses, high operating expenses, and maintaining adequate cash reserves.

Veru Inc. reports Q4 earnings, pursues partnerships for drug development

Veru Inc. reported a decrease in net revenues but secured significant funding through a successful public offering. Their drug development program, particularly enobosarm and sabizabulin, holds promise for multiple medical applications. The pursuit of partnerships and the potential for combination treatments present opportunities for future growth.

Veru Inc. reports Q1 growth, seeks partners for enobosarm study

Veru Inc. demonstrates financial progress and strategic initiatives in drug development, positioning itself for future growth and innovation.
The company's focus on enobosarm's potential in weight loss and oncology, along with seeking partnerships, reflects a proactive approach to advancing its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

Clearside Biomedical

Innoviva

Mannatech

Oramed Pharmaceuticals

United Therapeutics

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first on InvestorPlace.

7 Top-Rated Pharmaceutical Stocks To Invest in for October

MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin (VERU-111) in 80 men with metastatic castration resistant prostate cancer who have progressed on at least one novel androgen receptor targeting agent were presented at the European Society for Medical Oncology (ESMO) Congress 2021 being held September 16-21, 2021. Sabizabulin is a new oral chemical entity that represents a novel class of agents that target unique binding sites on microtubules to disrupt both the cytoskeleton and androgen receptor transport.

Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

MIAMI, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the following upcoming healthcare investor conferences.

Veru to Present at Three Upcoming Healthcare Investment Conferences

An analyst raised his price target for the stock.

Why Veru Stock Vaulted Higher Today

An analyst argues that the company has far more value than many realize.

Why Veru Stock Blasted Higher on Friday

Veru, Inc. (VERU) CEO Mitchell Steiner on Q3 2021 Results - Earnings Call Transcript

Veru Inc (NASDAQ: VERU) reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million. FC2 prescription net revenues climbed 150% Y/Y to $13.5 million.

Veru Stock Gains After Q3 Result Tops Estimates

Shares of Veru (NASDAQ:VERU) rose 13.2% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 40.00% over the past year to ($0.03), which beat the estimate of ($0.06).

Veru: Q3 Earnings Insights

--Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs—

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Veru Inc. (VERU) Q3 Earnings Expected to Decline

MIAMI, July 29, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it will report financial results for its fiscal 2021 third quarter on Thursday, August 12, 2021, before the market opens. Veru's management will host a conference call that same day at 8 a.m. ET to review the Company's performance and to answer questions. The call will also be accessible via webcast.

Veru to Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call on August 12th

MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical results from the ongoing Phase 1b/2 clinical study of sabizabulin (VERU-111), an oral cytoskeleton disruptor being evaluated for the treatment of metastatic castration resistant prostate cancer in men who progressed on an androgen receptor targeting agent, were accepted for presentation at the European Association of Urology 36th Annual Congress. The Congress is being held virtually from July 8-12, 2021.

Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress

--Sabizabulin is a novel oral androgen receptor transport disruptor-- -- In Phase 1b/2 clinical study, sabizabulin was well tolerated with significant antitumor efficacy in metastatic castration resistant prostate cancer patients who have also become resistant to abiraterone or enzalutamide, but prior to IV chemotherapy--                   --Phase 3 clinical study will be conducted in 45 clinical centers across the United States-- MIAMI, June 25, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it has enrolled the first patient in its Phase 3 VERACITY clinical trial of sabizabulin, an oral, first-in-class, new chemical entity, androgen receptor transport disruptor (targets and inhibits microtubules to disrupt androgen receptor transport into the nucleus), for metastatic castration and androgen receptor targeting agent resistant prostate cancer.

Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer

--VERU-100 formulated to address the clinical limitations of currently available androgen deprivation therapy-- --The Phase 2 clinical trial is expected to be completed by 2H calendar 2021--

Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer

Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent, in heavily pre-treated breast cancer patients. Data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting.

Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer Patients

-- In Phase 2 study, enobosarm, an oral selective androgen receptor (AR) agonist, had the most significant antitumor effects in heavily pretreated AR+ER+ metastatic breast cancer subjects with ≥ 40% AR expression in cancer tissue -- -- Companion diagnostic test to measure AR may be used to select AR+ER+HER2- metastatic breast cancer subjects most likely to benefit from enobosarm treatment--

Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting

-- Sabizabulin, an oral selective cytoskeleton disruptor, demonstrated good safety, significant evidence of antitumor efficacy, and that chronic administration is feasible in ongoing Phase 1b/2 study of 80 men -- -- Phase 3 VERACITY study to evaluate sabizabulin treatment in men who have metastatic castration prostate cancer and have also progressed following at least one androgen receptor targeting agent planned to start this month --

Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual Meeting

MIAMI, May 25, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Jefferies Virtual Healthcare Conference. The presentation will be available through the Conference on Tuesday, June 1st at 8:00 a.m. ET.

Veru to Present at the Jefferies Virtual Healthcare Conference

-- Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeting agent, treatment is dependent on the magnitude of expression of androgen receptor (AR) in breast cancer tissue -- -- Presentation of Phase 1b/2 updated clinical trial results of sabizabulin (VERU-111), an oral androgen receptor transport disruptor, in metastatic castration and androgen receptor targeting agent resistant prostate cancer --

Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Veru Inc (NASDAQ: VERU) has enrolled the first patient in its Phase 3 clinical trial evaluating sabizabulin (VERU-111) in high-risk hospitalized COVID-19 patients. Sabizabulin an oral cytoskeleton disruptor with anti-inflammatory and anti-viral properties.

Veru Starts Enrollment In Late-Stage Sabizabulin Trial For COVID-19

—Sabizabulin is a novel oral agent with both anti-viral and anti-inflammatory activities—

Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients

Veru, Inc. (VERU) CEO Mitchell Steiner on Q2 2021 Results - Earnings Call Transcript

Veru Inc (NASDAQ: VERU) reported a Q1 EPS loss of ($0.04), which met the analyst consensus estimate. The loss is wider than ($0.01) net loss a year ago.

Veru's FC2 Prescription Sales Boost Q2 Revenues

Shares of Veru (NASDAQ:VERU) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share fell 300.00% over the past year to ($0.04), which were in line with the estimate of ($0.04).

Veru: Q2 Earnings Insights

-- First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients-- --New Drug Application Accepted for Review by FDA for Proprietary TADFIN Daily Oral Dosing Combination for BPH; PDUFA Date December 2021--

News for Veru Stock (VERU)